Christopher Willett

Positions:

Chair, Department of Radiation Oncology

Radiation Oncology
School of Medicine

Mark W. Dewhirst Distinguished Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Professor of Radiation Oncology

Radiation Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1977

Tufts University

M.D. 1981

Tufts University

Grants:

Cancer Care Quality Measures: Diagnosis and Treatment of Colorectal Cancer

Administered By
Institutes and Centers
Awarded By
Agency for Healthcare Research and Quality
Role
Investigator
Start Date
End Date

Angiogenic Profile of Rectal Cancer

Administered By
Radiation Oncology
Awarded By
National Cancer Institute
Role
Principal Investigator
Start Date
End Date

Publications:

The role of department chair

The leadership position of a departmental chair can be a positive and rewarding opportunity. These rewards principally stem from the success of the faculty, trainees, staff, and everyone supporting the department. With healthcare reform and the constraints of the federal budget, increasing attention and time has become directed toward administrative management. Formal courses and training in executive leadership and business management may be helpful in enhancing knowledge and skills in these disciplines. There are multiple and often competing constituencies and agendas requiring thoughtful strategies to achieve departmental goals. The objectives of the chair are advancing patient care, education, and research as well as a continual presence and visibility in the department. The true excellence of a department is achieved by the innovation of its faculty and trainees.
Authors
Willett, CG; Le, QT
MLA Citation
Willett, C. G., and Q. T. Le. “The role of department chair.” Career Development in Academic Radiation Oncology, 2021, pp. 319–26. Scopus, doi:10.1007/978-3-030-71855-8_23.
URI
https://scholars.duke.edu/individual/pub1570288
Source
scopus
Published Date
Start Page
319
End Page
326
DOI
10.1007/978-3-030-71855-8_23

Pancreatic cancer

MLA Citation
Palta, M., et al. “Pancreatic cancer.” Clinical Radiation Oncology: Indications, Techniques, and Results, 2017, pp. 409–28.
URI
https://scholars.duke.edu/individual/pub1547479
Source
scopus
Published Date
Start Page
409
End Page
428

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a "watch-and-wait" nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
Authors
Benson, AB; Venook, AP; Al-Hawary, MM; Azad, N; Chen, Y-J; Ciombor, KK; Cohen, S; Cooper, HS; Deming, D; Garrido-Laguna, I; Grem, JL; Gunn, A; Hecht, JR; Hoffe, S; Hubbard, J; Hunt, S; Jeck, W; Johung, KL; Kirilcuk, N; Krishnamurthi, S; Maratt, JK; Messersmith, WA; Meyerhardt, J; Miller, ED; Mulcahy, MF; Nurkin, S; Overman, MJ; Parikh, A; Patel, H; Pedersen, K; Saltz, L; Schneider, C; Shibata, D; Skibber, JM; Sofocleous, CT; Stotsky-Himelfarb, E; Tavakkoli, A; Willett, CG; Gregory, K; Gurski, L
MLA Citation
Benson, Al B., et al. “Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 20, no. 10, Oct. 2022, pp. 1139–67. Pubmed, doi:10.6004/jnccn.2022.0051.
URI
https://scholars.duke.edu/individual/pub1554597
PMID
36240850
Source
pubmed
Published In
J Natl Compr Canc Netw
Volume
20
Published Date
Start Page
1139
End Page
1167
DOI
10.6004/jnccn.2022.0051

Pancreatic adenocarcinoma.

Authors
Tempero, MA; Arnoletti, JP; Behrman, S; Ben-Josef, E; Benson, AB; Berlin, JD; Cameron, JL; Casper, ES; Cohen, SJ; Duff, M; Ellenhorn, JDI; Hawkins, WG; Hoffman, JP; Kuvshinoff, BW; Malafa, MP; Muscarella, P; Nakakura, EK; Sasson, AR; Thayer, SP; Tyler, DS; Warren, RS; Whiting, S; Willett, C; Wolff, RA; NCCN Pancreatic Adenocarcinoma,
MLA Citation
Tempero, Margaret A., et al. “Pancreatic adenocarcinoma.J Natl Compr Canc Netw, vol. 8, no. 9, Sept. 2010, pp. 972–1017. Pubmed, doi:10.6004/jnccn.2010.0073.
URI
https://scholars.duke.edu/individual/pub919695
PMID
20876541
Source
pubmed
Published In
Jnccn Journal of the National Comprehensive Cancer Network
Volume
8
Published Date
Start Page
972
End Page
1017
DOI
10.6004/jnccn.2010.0073

Anal cancer

MLA Citation
Czito, B. G., et al. “Anal cancer.” Clinical Radiation Oncology: Indications, Techniques, and Results, 2017, pp. 466–79.
URI
https://scholars.duke.edu/individual/pub1547478
Source
scopus
Published Date
Start Page
466
End Page
479